These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27687641)

  • 1. Antibiotics in late clinical development.
    Fernandes P; Martens E
    Biochem Pharmacol; 2017 Jun; 133():152-163. PubMed ID: 27687641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery research: the scientific challenge of finding new antibiotics.
    Livermore DM;
    J Antimicrob Chemother; 2011 Sep; 66(9):1941-4. PubMed ID: 21700626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M; Mossialos E
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract]   [Full Text] [Related]  

  • 8. The productivity crisis in pharmaceutical R&D.
    Pammolli F; Magazzini L; Riccaboni M
    Nat Rev Drug Discov; 2011 Jun; 10(6):428-38. PubMed ID: 21629293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fix the antibiotics pipeline.
    Cooper MA; Shlaes D
    Nature; 2011 Apr; 472(7341):32. PubMed ID: 21475175
    [No Abstract]   [Full Text] [Related]  

  • 11. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
    Spellberg B; Sharma P; Rex JH
    Nat Rev Drug Discov; 2012 Feb; 11(2):168. PubMed ID: 22293569
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance to antibiotics: are we in the post-antibiotic era?
    Alanis AJ
    Arch Med Res; 2005; 36(6):697-705. PubMed ID: 16216651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sources of novel antibiotics--aside the common roads.
    Donadio S; Maffioli S; Monciardini P; Sosio M; Jabes D
    Appl Microbiol Biotechnol; 2010 Dec; 88(6):1261-7. PubMed ID: 20865256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Something old, something new: revisiting natural products in antibiotic drug discovery.
    Wright GD
    Can J Microbiol; 2014 Mar; 60(3):147-54. PubMed ID: 24588388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
    Kesselheim AS; Outterson K
    Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance diagnosis and the changing economics of antibiotic discovery.
    McAdams D
    Ann N Y Acad Sci; 2017 Jan; 1388(1):18-25. PubMed ID: 28072904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New advances in antibiotic development and discovery.
    Alekshun MN
    Expert Opin Investig Drugs; 2005 Feb; 14(2):117-34. PubMed ID: 15757391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial R&D incentives.
    Laxminarayan R; Powers JH
    Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
    [No Abstract]   [Full Text] [Related]  

  • 19. The drug-resistant bacteria that pose the greatest health threats.
    Willyard C
    Nature; 2017 Feb; 543(7643):15. PubMed ID: 28252092
    [No Abstract]   [Full Text] [Related]  

  • 20. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
    Brogan DM; Mossialos E
    Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.